# Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies

> **NCT00460694** · PHASE1,PHASE2 · COMPLETED · sponsor: **Singapore General Hospital** · enrollment: 24 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
- Non Hodgkin's Lymphoma
- Hodgkin's Disease
- Myelodysplastic Syndrome
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** infusion of allogeneic CIK cells

## Key facts

- **NCT ID:** NCT00460694
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460694, "Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00460694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*